Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
205 hedge funds and large institutions have $2.2B invested in Amicus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 83 increasing their positions, 51 reducing their positions, and 37 closing their positions.
197% more call options, than puts
Call options by funds: $7.67M | Put options by funds: $2.58M
63% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 51
1.67% more ownership
Funds ownership: 105.96% → 107.63% (+1.7%)
3% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 37
0% less funds holding
Funds holding: 206 → 205 (-1)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
35% less capital invested
Capital invested by funds: $3.36B → $2.2B (-$1.16B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$41.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$33.6M |
| 3 |
Primecap Management
Pasadena,
California
|
+$23.9M |
| 4 |
BlackRock
New York
|
+$23.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$49.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.1M |
| 4 |
HCM
Highline Capital Management
New York
|
-$18.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$9.26M |
FOLD Hedge Fund Activity: Q3 2019 in Review
205 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2019, worth a combined $2.2B — down 35% from $3.36B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new FOLD positions and 37 closed out — a net gain of 1 holder — while 83 added to existing stakes and 51 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $41.4M. The largest seller was Marshall Wace North America, cutting an estimated $49.9M.
- 205 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2019, down from 206 in Q2 2019.
- Funds reported $2.2B of Amicus Therapeutics stock for Q3 2019, down 35% quarter-over-quarter.
- 38 funds opened new Amicus Therapeutics positions in Q3 2019 and 37 closed out, a net change of +1 holder.
- The largest Amicus Therapeutics buyer in Q3 2019 was Morgan Stanley, an estimated $41.4M added.
- The largest Amicus Therapeutics seller in Q3 2019 was Marshall Wace North America, an estimated $49.9M sold.
Based on aggregated 13F filings for Q3 2019.